These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35953195)

  • 1. Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies.
    Wu A; Ansari AS; Uludaǧ H; Jiang X
    Methods Cell Biol; 2022; 171():1-22. PubMed ID: 35953195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
    Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
    Adnan Awad S; Dufva O; Klievink J; Karjalainen E; Ianevski A; Pietarinen P; Kim D; Potdar S; Wolf M; Lotfi K; Aittokallio T; Wennerberg K; Porkka K; Mustjoki S
    Cell Rep Med; 2024 May; 5(5):101521. PubMed ID: 38653245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
    Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
    Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
    Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
    Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
    Mojtahedi H; Yazdanpanah N; Rezaei N
    Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.
    Skorski T
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1(0 1):23-9. PubMed ID: 21299457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
    Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
    Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.
    Al Hamad M
    F1000Res; 2021; 10():1288. PubMed ID: 35284066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
    Wu A; Liu X; Fruhstorfer C; Jiang X
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.